Register for our free email digests:
Latest From Vernalis PLC
A look at recent developments tracked by the Complete Response Letters chart on the Pink Sheet's US FDA Performance Tracker.
Keeping Track: Zelboraf Takes Breakthrough Path For Rare Blood Disease; Teva Resubmits Generic EpiPen
The latest drug development news and highlights from our US FDA Performance Tracker.
Emerging Company Profile: CEO Richard Miller, who co-founded Idec and Pharmacyclics, explains Corvus's approach of building a pipeline around an emerging target in cancer immunity that may be complementary to checkpoint inhibitors and other therapies.
The Sanford Burnham Prebys institute is driving innovation in areas like neurodegenerative disease and immuno-oncology. Plus the latest tech transfer deals: two in cancer, one in asthma/allergies and another in lipid nanoparticle technology.
- Therapeutic Areas
- Neurology, Nervous System
- Respiratory, Pulmonary
- Western Europe
- Parent & Subsidiaries
- Vernalis PLC
- Senior Management
Ian Garland, CEO
David Mackney, CFO
Mike Wood, Dir., Research
Sandford Sommer, Pres. & COO
- Contact Info
Phone: (44) 118 938 0000
100 Berkshire Pl.
Winnersh, RG41 5RD
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.